A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy

Inclusion Criteria: * Weigh \>=25 kilograms * Diagnosis of epilepsy within 3 months prior to study entry or recurrence of epilepsy while off of anit-epileptic drugs * No more than two documented seizures during the three-month retrospective baseline phase * may have experienced seizures prior to the three-month, retrospective baseline phase * Patients with partial-onset seizures, with or without a secondarily generalized component, and generalized seizures, including tonic-clonic (grand mal), tonic, clonic, juvenile myoclonic epilepsy (impulsive petit mal) and myoclonic epilepsy * Receiving either no other concomitant anti-epileptic drug (AED) or be on one standard AED. Exclusion Criteria: * Patients who do not have epilepsy * Patients with absence (petit mal) or atypical absence seizures, epilepsia paritlis continua, cluster pattern or serial seizures * Patients with progressive neurological or degenerative disorder * Patients with significant history of unstable medical diseases * Patients with a drug allergy or hypersensitivity to carbonic anhydrase inhibitors or sulfa drugs * Patients with history of alcohol or drug abuse within past one year * Patients with a history of suicide attempt within past one year.